Ajanta Pharma promoter releases pledge on 6,910 equity shares
Ravi Agrawal disclosed the release of pledge on 6,910 Ajanta Pharma shares on August 19, 2026, following earlier reductions in August. The total encumbered stake for the trust stood at 1.18% of total share capital after the early August transactions. Other promoters, including Aayush M Agrawal, continue to hold significant pledged positions, with Aayush's trust having 10.83% of its holdings encumbered.
*this image is generated using AI for illustrative purposes only.
Ravi Agrawal, acting as trustee for the Ravi Agrawal Trust, has released pledge on 6,910 equity shares of Ajanta Pharma . The promoter disclosed the transaction to the Bombay Stock Exchange and the National Stock Exchange on August 19, 2026, citing "Excess Pledge" as the primary reason for the release.
This latest disclosure follows a series of unpledging activities in early August 2026, which reduced the total encumbered stake held by the trust from 1,535,096 (1.23% of total share capital) to 1,480,300 (1.18% of total share capital) as of August 12. As per the disclosure under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, the shares were pledged against business financing obligations.
Transaction Details
The most recent release of encumbrance occurred on August 19, 2026. This transaction adds to the cumulative reduction in pledged shares observed over the preceding two weeks.
| Date | Lender | Shares Released | Post-Event Encumbered Shares | % of Total Share Capital |
|---|---|---|---|---|
| August 6, 2026 | Deutsche Investments India Pvt Ltd | 130 | 1,534,966 | 1.23% |
| August 7, 2026 | Bajaj Finance Limited | 28,366 | 1,506,600 | 1.21% |
| August 11, 2026 | Infina Finance Limited | 23,800 | 1,482,800 | 1.19% |
| August 12, 2026 | Tata Capital Limited | 1,300 | 1,481,500 | 1.19% |
| August 12, 2026 | Infina Finance Limited | 1,200 | 1,480,300 | 1.18% |
| August 19, 2026 | Not specified in source | 6,910 | Not specified in source | Not specified in source |
Previous transactions were facilitated through Barclays Securities (India) Private Limited as the depository participant.
Promoter Holding Structure
The disclosure table provides a snapshot of the broader promoter group holdings as of the reporting date. While Ravi Agrawal’s trust saw a reduction in pledged stakes, other promoters maintained their positions:
- Gabs Investments Pvt Ltd: Holds 12,588,393 shares (10.07%), with 2,770,000 shares (2.22%) remaining encumbered.
- Yogesh M Agrawal (Trustee): Holds 18,078,147 shares (14.47%) with no encumbrances.
- Rajesh M Agrawal (Trustee): Holds 18,078,148 shares (14.47%) with no encumbrances.
- Aayush M Agrawal (Trustee): Holds 14,112,924 shares (11.29%), with a significant portion of 13,532,924 shares (10.83%) still encumbered.
Ganga Exports, represented by partners Yogesh Agrawal, Rajesh Agrawal, and Ravi Agrawal, holds 3,348,261 shares (2.68%) with no pledges reported.
Historical Stock Returns for Ajanta Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.41% | +1.10% | +0.88% | +19.87% | +37.43% | +146.32% |
What are the specific business financing obligations that prompted the initial pledging, and how does the current reduction impact the company's overall debt-to-equity ratio?
Given that Aayush M Agrawal’s trust still has over 10.8% of the total share capital encumbered, what is the risk profile for the promoter group if Ajanta Pharma's stock price declines further?
How might the continued unpledging of shares by Ravi Agrawal Trust influence institutional investor sentiment regarding the promoter group's financial health and liquidity?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
